Vaxart COVID-19 vaccine
From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Other names | VXA-CoV2-1, VXA-CoV2-1.1-S |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[2][3][4]
References
[edit]- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
Scholia has a profile for Vaxart COVID-19 vaccine (Q110269782).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from December 2021
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine